Modified-release supplement technology covers the encapsulation, coating and matrix systems used to control where, when and how an active is released in vivo. Enteric coating protects gastric-acid-degraded actives (probiotics, enzymes) and reduces palatability issues (fish oil burp-back), using methacrylic acid copolymers (Eudragit L/S/FS series with defined pH thresholds — L 100 dissolves at pH ≥6.0, L 100-55 at pH ≥5.5, S 100 at pH ≥7.0), hypromellose phthalate, hypromellose acetate succinate, cellulose acetate phthalate or polyvinyl acetate phthalate. USP <2040> Disintegration and Dissolution of Dietary Supplements defines the two-stage test (2 h in 0.1 N HCl acid stage with <10% release, then buffer stage at target pH with >75% release in 45-60 min). Microencapsulation encloses individual active particles at micrometre scale via spray drying, fluid-bed coating, coacervation or emulsion solidification — matrix materials include gum arabic, modified starch, maltodextrin, gelatin, chitosan, alginate, whey protein, lipid systems. Liposomal delivery uses phospholipid vesicles (soy/sunflower/egg lecithin) — the recurring compliance failure is 'liposomal' label claims on products lacking verified phospholipid bilayer vesicle structure (often simple oil-in-water emulsions or micelle systems), exposing brands to FDA Warning Letters and class-action litigation; defensible liposomal claims require characterisation by cryo-electron microscopy and dynamic light scattering with encapsulation efficiency and vesicle-size distribution evidence, with head-to-head PK study evidence for comparative bioavailability claims. Sustained-release matrix systems use hydrophilic polymers (hypromellose, alginate, xanthan, CMC) or hydrophobic matrices (waxes, hydrogenated oils, ethylcellulose) with multi-time-point USP <2040> dissolution validation and discriminating method development. Manufacturing controls include polymer/lipid raw material specification with lot consistency, validated process parameters (coating-bed temperature, spray rate, atomisation, drying, curing), in-process controls (coating weight gain, particle size, granule size), finished-product dissolution and content uniformity per USP <905>, and stability-indicating dissolution across shelf life because modified-release profiles often drift with polymer ageing.

Regulatory anchors

USP <2040>
USP <905>
ICH Q6A
21 CFR 111

Industries that live with this

Dietary Supplements Pharmaceutical

How V5 handles it

QMS — quality engineered into every action, not bolted on.

Because V5 owns the operator action, the QMS sees the data the second it’s captured — not at the end of the shift.

From the first pull to a signed CoA in your customer's hands.

One connected QC loop. The analyst runs the sample on the kiosk; the result lands on the chart; an out-of-spec opens its own investigation, spawns a CAPA, holds the batch and routes the disposition; the released lot's Certificate of Analysis is built from real values, signed under §11.50, and delivered to the customer portal with every view logged. No spreadsheets. No retyping. No quiet edits.

Document control with hard kiosk-level training enforcement.

Versioned SOPs are only useful if operators are actually trained on the current version. V5 enforces it at the kiosk.

QC release — your reviewer sees only what failed.

By the time a batch reaches QC, every signed step has already rolled up. Your reviewer reviews-by-exception, signs, and releases — with the deviations and CAPAs already linked.